Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409559 | 0.86 | ALDH1A1 (0.43) | NQO2ALDH1A1GLAMAPTHPGD | |
| Hydrochloric Acid SCHEMBL8134377 | 0.85 | ALDH1A1 (0.42) | NQO2ALDH1A1GLAMAPTHPGD | |
| Hydrochloric Acid SCHEMBL30274776 | 0.85 | ALDH1A1 (0.42) | NQO2ALDH1A1GLAMAPTHPGD | |
| SCHEMBL29827623 | 0.80 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL28593235 | 0.75 | KMT2A (0.41) | NQO2ALDH1A1GLAMAPTHPGD | |
| SCHEMBL5904470 | 0.73 | PARP1 (0.35) | ALDH1A1ACHEMEN1KMT2A | |
| SCHEMBL5330437 | 0.73 | NQO2 (0.33) | NQO2MEN1KMT2A | |
| Anthracene SCHEMBL27804282 | 0.73 | MEN1 (0.36) | ALDH1A1MEN1KMT2A | |
| SCHEMBL686691 | 0.72 | MEN1 (0.35) | ALDH1A1MEN1KMT2A | |
| SCHEMBL17220622 | 0.72 | MEN1 (0.35) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877455-B1 | FUSED QUINONIC COMPOUNDS | CT ATLANTICO DEL MEDICAMENTO S A CEAMED S A (ES) | 2016-08-17 | — | — | EP | disclosed |
| US-20150175585-A1 | FUSED QUINONIC COMPOUNDS | CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED S.A.) (ES) | 2015-06-25 | — | — | US | disclosed |
| EP-2877455-A1 | FUSED QUINONIC COMPOUNDS | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2015-06-03 | — | — | EP | disclosed |
| WO-2014016314-A1 | FUSED QUINONIC COMPOUNDS | CENTRO ATLANTICO DEL MEDICAMENTO S.A (CEAMED, S.A) (ES) | 2014-01-30 | — | — | WO | disclosed |
| EP-2690094-A1 | Fused quinonic compounds | Centro Atlantico del Medicamento S.A (Ceamed, S.A) (ES) | 2014-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175585-A1 | FUSED QUINONIC COMPOUNDS | STAT3, STAT1, JAK2 | NQO2 337/4885ALDH1A1 3575/4885GLA 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.